DeepMind’s AlphaFold Protein Structure Database

Several days ago, DeepMind (sister company of Google) released its much awaited AlphaFold 2 protein structure database. To be accurate, the project was in partnership with the European Molecular Biology Laboratory (EMBL).

The original AlphaFold project commenced in December 2018. The Nature article provides a full summary of this latest breakthrough. DeepMind’s CEO and founder is Dr. Demis Hassabis.

The British company became renowned due to its AlphaGo and AlphaZero programs. These programs taught themselves Go, Chess and Shogi through playing themselves over several days. They were then able to defeat the world’s best human and supercomputer players of those games.

I am very surprised that this groundbreaking development was not mentioned by any readers. It will likely have positive implications for future hair loss treatments. Interestingly, reader “Quentin” recently made a very useful comment about amino acids, which are closely related to proteins.

AlphaFold 2 Highlights

Among the highlights of this open access online freely available AlphaFold database:

“This will be one of the most important datasets since the mapping of the Human Genome.” — Dr. Ewan Birney (EMBL-EBI Director).

  • DeepMind’s AlphaFold 2 AI tool has given 3-D structure to 350,000 proteins.
  • This includes a map of the roughly 20,000 proteins expressed by the human genome. Also known as the proteome.
  • AlphaFold is already helping scientists accelerate drug discovery.
  • Over the coming months. DeepMind plans to vastly expand the coverage to almost every sequenced protein known to science (over 100 million structures in the UniProt database).
  • This computational work represents a stunning advance in the 50-year old protein-folding problem in biology.
  • It will change everything (?).

“With this resource freely and openly available, the scientific community will be able to draw on collective knowledge to accelerate discovery, ushering in a new era for AI-enabled biology.” — Dr. Paul Nurse (Director of the Francis Crick Institute).

Hair Loss Proteins

It seems like this technology is ripe for helping speed up the development of hair loss treatments. And helping understand the reasons for androgenetic alopecia.

For a long time, many people have suggested that a hair loss cure does not have to entail just complete annihilation of (DHT). For example, see my post on the Krox20 (EGR2) protein.

Just for the heck of it, I did a search for “hair” in the database. It came up with 175 results:

AlphaFold 2 Search
AlphaFold 2 Protein Search Results.

Other Open Source Resources

We are increasingly seeing free online databases and open access resources that benefit hair loss researchers. In addition to the general DeepMind/AlphaFold GitHub, we also have hair specific ones such as the BiernaskieLab GitHHub.

You also have resources such as Driskell Lab’s skinregeneration.org where you can search for large datasets related to scarring and regenerative tissues. See my related post on skin regeneration, wound healing and hair growth.

Dutasteride Works when Finasteride Fails

In 2021, the single most important drug in the fight against hair loss remains Dutasteride (brand name Avodart). However, it is not approved for that use by the US FDA. I have written numerous past posts on Dutasteride to treat male pattern hair loss.

The most useful one remains my Avodart reviews for hair loss post due to the vast number of reader comments. Also see my posts on Dutasteride injections (also knows as mesotherapy).

Dutasteride v/s Finasteride Dosage and DHT Reduction
Dutasteride reduces more Dihydrotestosterone (DHT) than Finasteride.

Dutasteride more Potent than Finasteride

Every week I search PubMed for the latest papers on Dutasteride and hair loss. This week, I discovered an important new June 2021 study that was just published. It is titled:

“Change in hair growth-related gene expression profile in human
isolated hair follicles induced by 5-alpha reductase inhibitors: dutasteride and finasteride.”

The findings of this study are quite interesting and related to something similar that I published in 2014 (see old post at bottom). Note that this latest work was led by Japanese researchers and funded by GlaxoSmithKline (GSK), the manufacturer of Avodart.

It is encouraging to see GSK still interested in Avodart for hair loss. They will almost certainly not try to get the drug approved to treat hair loss in the US or EU. To date, Japan and South Korea remain the only countries where you can officially use Dutasteride to treat hair loss.

In the rest of the world, the drug is prescribed to treat enlarged prostates (BPH) in older men. For hair loss, you need off-label prescriptions. Also note that on average, side effects from Dutasteride are worse than from Finasteride.

Although GSK is headquartered in the UK, this particular research was affiliated with the company’s Singapore subsidiary. Professor Manabu Ohyama (who I have covered in the past) gave advice on the study protocol and methodology.

Key Findings

The key findings of this latest paper on Dutasteride (and Finasteride) include:

  • Dutasteride and Finasteride both suppressed the negative effects of testosterone on hair-related gene expression.
  • In particular, the gene expression for growth factors FGF7, IGF1 and WNT5a.
  • Dutasteride may have a stronger inhibitory potency to increase growth factor expression than Finasteride.
  • Dutasteride’s greater efficacy on hair growth in comparison to Finasteride is possibly due to the inhibition of 5α-reductase Type 1; or due to greater inhibition of 5α-reductase Type 2 by Dutasteride when compared to Finasteride. My note: most likely both issues are at play per next conclusion.
  • The authors claim that there results suggest that: “Type I 5 alpha reductase may play an important role in hair growth along with Type II 5 alpha reductase.

I forgot that this issue of the significance of Type 1 5α-reductase in relation to hair loss is still unresolved. My guess is that Type 1 is significant, but not quite as significant as Type 2. Dutasteride attacks both Type 1 and Type 2, while Finasteride only attacks the latter.

Make sure to also read my post on destroying androgen receptors on the scalp.

June 8, 2014

Dutasteride Works when Finasteride Fails

An interesting study by South Korean scientists was recently published in “The International Journal of Dermatology”.  It measured the effect of Dutasteride on men with androgenetic alopecia unresponsive to treatment with Finasteride.

They took 35 balding people who did not see any improvement while on Finasteride 1 mg/day for 6 months. They then put those same people on Dutasteride 0.5 mg/day for 6 months.  31 of those patients completed the 6 months of treatment.  Hopefully, the 4 who stopped treatment did not stop due to experiencing significant side effects.

Over three-quarters of these 31 patients saw at least some increase in hair count. Only 1 patient had a marked improvement, while 6 patients had a moderate improvement and 17 patients had a slight improvement. The remaining 7 patients did not see any improvement or worsening.

Side effects included transient sexual dysfunction in 6 patients (17.1%).